Lyme disease (LD) carries a substantial financial burden for both patients and the health care system, suggests a new retrospective cohort study, with costs driven largely by cases that progress beyond early-stage infection.
The study, published yesterday in JAMA Network Open, analyzed the electronic health records of more than 70,000 people diagnosed as having LD from 2016 to 2022. They were compared with more than 210,000 patients in the control group who did not have LD.
Researchers compared costs for patients with early-stage disease with those who developed disseminated disease, which is when the disease progresses beyond the initial stages and often involves neurologic, cardiac, or joint complications.
Cost per episode $6,800 for later-stage disease
The direct health care costs of LD were substantial, note the researchers. Mean direct medical costs per each LD episode were $2,227, but that number rose to $6,833 for patients with disseminated disease, compared with $695 for those with localized, early-stage infections. While only 22% of LD patients have disseminated disease, they accounted for nearly 70% of total Lyme-specific health care costs.
During the six-month follow-up, mean total all-cause health care costs for LD patients were nearly $4,100 more than for patients in the matched control group. Out-of-pocket costs also increased after diagnosis. Mean patient-incurred costs associated with LD ranged from $188 to $399, with higher burdens seen among those with disseminated illness.
“Extrapolating to the US population in high-incidence states, annual costs of LD could range between $591 million and $1.05 billion (2022 dollars), with $411 to $771 million attributable to disseminated disease,” write the researchers, concluding that effective prevention strategies could help reduce both patient and health care–level costs associated with LD.